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Interleukin-2 receptor (IL-2R) signaling is essential
for T regulatory (Treg) cell development and homeo-
stasis. Here, we show that expression of IL-2Rb
chains that lack tyrosine residues important for the
association of the adaptor Shc and the transcription
factor STAT5 in IL-2Rb-deficient mice resulted in
production of a normal proportion of natural Treg
cells that suppressed severe autoimmunity related
with deficiency in IL-2 or IL-2R. These mutant IL-
2Rb chains supported suboptimal and transient
STAT5 activation that upregulate the transcription
factor Foxp3 to normal amounts in natural, but not
induced, Treg cells. Nevertheless, gene expression
profiling revealed many targets in peripheral natural
Treg cells that were IL-2 dependent and a substantial
overlap between the Treg cell IL-2-dependent gene
program and the Treg cell transcriptional signature.
Collectively, these findings demonstrate that a crit-
ical, and perhaps minor, subset of IL-2-dependent
targets is indexed to a low IL-2R signaling threshold
and that a substantial proportion of the Treg cell gene
program is regulated by IL-2.
INTRODUCTION
The interaction of interleukin-2 (IL-2) with the interleukin-2
receptor (IL-2R) is important for T effector cells but is essential
for Treg cell development and homeostasis (Malek, 2008).
Indeed, the systemic lethal autoimmunity associated with defi-
ciency in IL-2, IL-2Ra (CD25), or IL-2Rb (CD122) is primarily
associated with defective Treg cell production (Malek et al.,
2002). These mice harbor immature CD4+ Foxp3lo CD25
T cells that do not suppress peripheral autoreactive T cells
(Bayer et al., 2007; Fontenot et al., 2005). IL-2 is critically
required in the thymus to promote Treg development in an
instructive manner, in part by upregulation of Foxp3 and CD25
(Burchill et al., 2008; Lio and Hsieh, 2008). IL-2 is also required
for the peripheral homeostasis of Treg cells (Bayer et al., 2005;
Setoguchi et al., 2005). Lower production of IL-2 defines one204 Immunity 30, 204–217, February 20, 2009 ª2009 Elsevier Inc.of the genetic factors rendering nonobese diabetic (NOD) mice
susceptible to autoimmune disease that leads to impaired Treg
cells (Yamanouchi et al., 2007). IL-2 is also necessary for the
generation of Foxp3+ induced-Treg (iTreg) cells from naive
conventional peripheral T lymphocytes (Davidson et al., 2007;
Zheng et al., 2007).
IL-2R signaling mechanisms have been most extensively
studied in various IL-2-responsive cell lines that approximate
activated effector T cells (Gaffen, 2001; Nelson and Willerford,
1998). IL-2 signal transduction is initiated upon ligand-induced
oligomerization of the IL-2R, consisting of IL-2Ra, IL-2Rb, and
gc (CD132). This event brings the cytoplasmic tail of IL-2Rb and
gc in close proximity with their associated Jak-1 and Jak-3
kinases, respectively, allowing phosphorylation of three key
tyrosines (Y) residues of IL-2Rb. Phosphorylation of Y338 (Y341
in themouse)permits recruitment of theadaptorShc,which leads
to activation of the MAPK and PI-3-kinase pathways, whereas
phosphorylation of Y392 and Y510 (Y395 and Y498 in themouse)
preferentially and predominately recruits the transcription factor
STAT5, thereby leading toactivation of STAT5-dependent genes.
This relationship is not strict and there appears tobe some redun-
dancy related to these tyrosine residues and pathways given that
STAT5 activation was associated with Y338 in some studies and
STAT5 activation has been reported to sustain PI-3-kinase acti-
vation independent of Shc (Lockyer et al., 2007). Importantly,
optimal IL-2-dependent T cell growth factor activity in IL-2-
responsive cell lines requires phosphorylation of all three tyro-
sines and signaling through these pathways.
Mostly indirect evidence supports an important and primary
role for IL-2-dependent activation of STAT5 in Treg cells. IL-2R
signaling in Treg cells leads only to STAT5 activation that is
due to phosphatase and tensin homolog (PTEN) inhibition of
the PI-3-kinase pathway (Bensinger et al., 2004; Walsh et al.,
2006). In mice that lack STAT5, Treg cells are reduced (Burchill
et al., 2003; Snow et al., 2003). Correspondingly, expression of
constitutively active STAT5 increased Treg cell numbers when
expressed in normal or Treg cell-deficient mice (Burchill et al.,
2003; Burchill et al., 2008). Only one study has directly linked
IL-2R-dependent activation of STAT5 and Treg cell production.
This study showed that mature Treg cells developed in Rag2/
chimeras after receiving Il2rb/ bone marrow that was trans-
duced with an truncated IL-2Rb chain that was designed to
selectively activate STAT5 (Burchill et al., 2007). However,
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tively short time frame of these experiments, signaling or
suppressive activity by these Treg cells was not studied. Thus,
the extent and exclusivity of STAT5 activation associated with
this engineered IL-2Rb chain and the durability of this type of
signaling with respect to Treg cell homeostasis and function
remain unclear.
Recent work has established a transcriptional signature for
Treg cells that in part critically depends upon Foxp3 and IL-2
(Gavin et al., 2007; Hill et al., 2007; Lin et al., 2007). The extent
that IL-2 controls the Treg gene signature has not been defined.
Given this issue and the little that is known concerning IL-2R
signalingmechanisms in Treg cells, the current study was under-
taken to directly investigate the contribution of IL-2R signaling in
Treg cell development, function, and homeostasis by examining
the capacity of cytoplasmic domain mutant IL-2Rb chains to
support Treg cell production. The activity of mutant IL-2Rb
chains was also compared between Treg cells and convention-
ally activated T lymphocytes. We find that Treg cells are effec-
tively indexed to a low IL-2R signaling threshold and that
a substantial fraction of the Treg cell transcriptional signature
depends upon IL-2R signaling.
RESULTS
Mice Expressing Mutant IL-2R b-Chains Lack Severe
Systemic Autoimmunity
To directly examine the contribution of IL-2R signaling on
primary T effector and Treg cells, we mutated Y341, or both
Y395 and Y498, to phenylalanine or deleted the H-region of the
cytoplasmic domain to generate IL-2Rs that are predicted to
predominantly activate Shc- or STAT5-dependent pathways,
respectively (Figure 1A). Additionally, all three key tyrosine resi-
dues together were mutated to block these pathways. These
constructs were expressed as transgenes in Il2rb/ mice in T
lineage cells under the control of the CD2-mini gene. Typically
two transgenic founders were identified and backcrossed to
C57BL/6 Il2rb/ mice. As a control, Il2rb/ mice were also
prepared that expressed transgenic wild-type (WT) IL-2Rb.
These mice are designated 2RbY341, 2RbY395,498, and
2RbY341,395,498, reflecting the Y/F mutations, 2RbDH or
2RbWT, and all data reported represent transgenic mice on the
Il2rb/ genetic background unless otherwise noted. Transgenic
IL-2Rbs were largely T cell lineage restricted given that IL-2Rb
was readily detected on essentially all thymocytes and mature
T cells in the lymph nodes (LNs) (Figure 1B) and spleen (not
shown) but was absent on the non-T cell fraction in these periph-
eral immune tissues.
These transgenic mice on the Il2rb/ genetic background
contained normal numbers of cells in the thymus (Figure 1C),
spleen (not shown), and LNs (Figure 1C). The distribution of
major T cells subsets was also predominantly normal in the
thymus and periphery as defined by CD4 and CD8 (Figure 1B).
One exception was a lower proportion and number of peripheral
CD8+ T cells as reflected by an increased CD4:CD8 ratio that
was most striking for 2RbY395,498, 2RbY341,395,498, and 2RbDH
mice (Figure 1B, right) and in part probably reflects impaired
IL-15 signaling through the mutant transgenic IL-2Rb chains, re-
sulting in decreased survival of CD8+ T cells (Surh et al., 2006).As expected, natural killer (NK) cells were greatly reduced in
the spleen (Figure 1D), given that these cells largely depend on
STAT5-dependent IL-15 signaling for their development in the
bone marrow (Waldmann and Tagaya, 1999). Greater numbers
of NK cells for the 2RbWT and the 2RbY341 mice may reflect
some activity of these transgenes in the thymus, which is
a secondary site of NK development (Di Santo and Vosshenrich,
2006). Thus, the expression of transgenicWT ormutant IL-2Rb in
all T lineage cells does not obviously alter the T cell compartment
probably because CD25 is absent on the largemajority of thymo-
cytes and peripheral T cells and CD25 is required for responsive-
ness to IL-2.
IL-2- or IL-2R-deficient mice uniformly exhibit a rapid lethal
autoimmune disease characterized by hyperproliferative periph-
eral T cells with an activated phenotype (Sadlack et al., 1993;
Suzuki et al., 1995; Willerford et al., 1995). When compared to
C57BL/6 Il2rb/ mice, which usually die by 8–12 weeks of
age, all these transgenic mice expressing mutant IL-2Rb were
effective breeders and overtly healthy (not shown), as long as
the transgenic IL-2Rb was expressed at an amount equally or
greater than that found on T cells in Il2rb+/ mice. The 2RbY341
and 2Rb395,498 lines were developed first and we have readily
maintained some of thesemice as long as 12–18months without
evidence of obvious disease. When specific characteristics
associated with autoimmunity in Il2rb/ mice were evaluated
for mice <16 weeks of age, each transgenic line contained
predominantly normal LN cellularity (Figure 1C), and their periph-
eral T cells did not show an extensively activated phenotype after
measuring CD44 expression for CD4+ and CD8+ T cells
(Figure 2A) and CD69 and CD62L expression for CD4 (Figures
2B and 2C) and CD8 (not shown) T cells. This phenotypic profile
indicates that these mice contain a mostly normal complement
of naive peripheral T cells. Furthermore, all transgenic Il2rb/
mice were not anemic (Figure 2D). When compared to littermate
controls, the CD4+ T cells from 2Rb395,498 (Figure 2C) and 2RbDH
(Figures 2A and 2C) mice exhibited a modest and statistically
significant increase in the percentages of cells bearing CD44hi
and/or CD69. However, after 14–16 weeks of age, a trend was
noted for increased percentages of CD69+ and CD62Llo CD4+
T cells for 2Rb395,498 and 2RbDH mice and for 2Rb395,498,
2Rb341,395,498, and 2Rb DH mice, respectively, whereas this was
rarely seen for 2RbY341mice (Figure 2E). This finding is consistent
with immune activation that is associated with autoimmunity.
Quantitative analysis of cell-surface IL-2Rb from Treg cells
bearing the mutant IL-2R b-chains from these predominantly
autoimmune free mice revealed expression comparable or
higher than in control Il2rb+/ or Il2rb+/+ mice (Figure S1). We
also identified two other 2RbY395,498 founders (#4 and #6), which
expressed transgenic mutant IL-2Rb at a lower amount than
found on Treg cells from Il2rb+/ mice but at a higher level than
found on the negative control, i.e., immature Treg cells in
Il2rb/ mice. Progeny from these two founders (2Rb395,498
founders 4 and 6) consistently exhibited symptoms of autoim-
munity that were generally comparable to those found in autoim-
mune Il2rb/ animals (Figure S2 and not shown). Data from
these two founders were not included anywhere else in this
report. Thus, at least for the 2RbY395,498 transgene, we found
a dose-response relationship in which protection from autoim-
munity correlated with increased expression of mutant IL-2Rb.Immunity 30, 204–217, February 20, 2009 ª2009 Elsevier Inc. 205
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IL-2R Signaling and T Regulatory CellsFigure 1. Characterization of Lymphocyte Cell Populations within Individual Transgenic Lines
(A) Scheme represents mutant IL-2Rb transgenes. Domains of IL-2Rb are listed above the model, in which TM refers to transmembrane.
(B) IL-2Rb expression by representative transgenic lines. Thymus and LNs were obtained from the indicated transgenic Il2rb/ mice and were assessed for
CD122 (IL-2Rb) expression after gating on the indicated populations of CD4+ and CD8+ cells. For reference, CD122 expression by normal WT C57BL/6 (B6) cells
was included. DN andDP are CD4CD8 or CD4+CD8+ thymocytes, respectively. Data are representative of two founders per transgenic line. The numbers to the
right of the dot plots represent the percentage of cells within the designated gated regions.
(C and D) Thymic and LN cellularity (C) and splenic NK cells (D) for the indicated transgenic lines. Data are mean ± SEM ofR6 mice/group <16 weeks of age
derived from at least six independent experiments.206 Immunity 30, 204–217, February 20, 2009 ª2009 Elsevier Inc.
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IL-2R Signaling and T Regulatory CellsFigure 2. Autoimmune Status of Transgenic Il2rb/ Mice Expressing Mutant IL-2Rb
The indicated IL-2Rb transgenic mice were assessed for peripheral T cells with an activated (A) CD44hi, (B) CD69+, or (C) CD62Llo phenotype or for (D) hemolytic
anemia. Controls were Il2rb+/ or Il2rb/ littermate mice. Data are mean ± SEM ofR7 mice/group <16 weeks of age, except for 2RbWT (n = 3) (A–C) and repre-
sentative of at least five mice/group in (D) and were derived from at least three independent experiments. As shown in (E), autoimmune status was also assessed
as a function of age for the indicated transgenic mice by enumerating the percentage of CD4+ T cells that were CD69+ or CD62Llo. The line in (E) represents the
value for two standard deviations above of the mean for littermate control mice. As shown in (F), hematoxylin-eosin-fixed sections of the indicated tissues were
examined for inflammatory infiltrates.The histopathological changes in older (>16 weeks)
2RbY395,498, 2RbY341,395,498, and 2RbDH mice often showed peri-
vascular lymphoplasmacytic inflammatory infiltrates in the lung
and salivary gland (Figure 2F), and less frequently showed themin the liver, colon, stomach, and pancreas. The severity of these
infiltrates usually ranged frommild to moderate, and representa-
tive examples of such infiltrates for the lung and salivary gland are
shown in Figure S3. Only the two oldest 2RbY341 mice showedImmunity 30, 204–217, February 20, 2009 ª2009 Elsevier Inc. 207
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IL-2R Signaling and T Regulatory CellsFigure 3. Natural and iTreg Cells from Mice Expressing Mutant IL-2Rb
(A) CD4+ Foxp3+ T cells within the thymus and LNs of the indicated mice were examined for CD25 (IL-2Ra) and CD122 (IL-2Rb) expression.
(B and C) The percentage (nR 5 mice/group) and expression of Foxp3 (nR 3 mice/group) (both in [B]) and the level of CD25 (R3 mice/group) for Foxp3+ T cells
(in [C]) in the thymus and LNs. Expression is expressed as mean fluorescent intensity (MFI). The MFI of staining by control Il2rb+/was normalized to a value of 1
and used to compare staining by T cells bearing mutant IL-2Rb.
(D) Production of Foxp3+ T cells after culture of spleen cells from the indicated mice with TGF-b and IL-2. Data in (B)–(D) are mean ± SEM for mice <16 weeks of
age that were derived from at least three independent experiments.infiltrates in the lung and salivary gland. These changes were
more frequent and even appeared in some younger (<16 weeks)
2RbY395,498, 2RbY341,395,498, and 2RbDH mice (Figure 2F). In addi-
tion, inflammatory infiltrates in various nonlymphoid tissues were
not usually accompanied by lymphoplasmatic hyperplasia in the
spleen and LNs, suggesting that these former differences may
precede obvious immune activation in secondary lymphoid
tissues. Inmarkedcontrast, younguntreated Il2rb/mice readily
showed extensive lymphoplasmatic hyperplasia in the spleen
and LNs and lymphocytic infiltrates in the liver and severe colitis
in the three oldestmice, but involvement of the salivary gland and
lung was less frequent and found in the youngest Il2rb/ mice.
Collectively, these functional and pathological analyses unex-
pectedly demonstrate that mutations of IL-2Rb, which are pre-
dicted to severely impair IL-2R signal transduction, are associ-
ated with a long life span and lack of severe autoimmunity.208 Immunity 30, 204–217, February 20, 2009 ª2009 Elsevier Inc.Mutant IL-2R b-Chains Support the Production
of Natural but Not iTreg Cells
Il2rb/ mice are characterized by containing a population of
immature CD4+Foxp3loCD25 T cells that are found at a mark-
edly reduced frequency, especially in the periphery, when
compared to the mature CD4+Foxp3hiCD25+ population in
normal WT mice (Bayer et al., 2007; Fontenot et al., 2005; Yu
and Malek, 2006). We confirmed that there was a consistent
50% lower (p = 0.0088, t test) proportion of Foxp3lo T cells in
the thymus of Il2rb/ mice. For transgenic Il2rb/ mice ex-
pressing each mutant IL-2R b-chain, a predominantly normal
proportion of mature CD4+Foxp3hiCD25+ Treg cells was found
in the thymus and LNs (Figures 3A and 3B), although the lower
percentage of thymic immature Treg cells in the Il2rb/ mice
did not reach statistical significance by the one-way ANOVA.
As the IL-2Rb transgenic mutant mice contained normal thymic
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translate to normal numbers of Treg cells. After gating the
CD4+Foxp3+ T cells in the thymus and LNs, essentially all these
Treg cells expressed transgenic IL-2Rb at amounts similar to
control WT Treg cells (Figure 3A).
A consequence of restoring IL-2R signaling within the imma-
ture Treg cells contained in IL-2Rb-deficient mice is upregulation
of Foxp3 and CD25 (Bayer et al., 2007). For thymic and periph-
eral Treg cells, each mutant IL-2R b-chain supported Foxp3
expression, as assessed by mean fluorescent intensity (MFI),
to a level comparable to that in control WT mice (Figure 3B).
Each mutant IL-2R b-chain also readily supported induction of
CD25 on the CD4+Foxp3+ T cells in the thymus and periphery
(Figure 3A), and this induction is striking in comparison to the
minimal amount of CD25 associated with immature Treg cells
within IL-2Rb/ mice. However, each mutant IL-2R b-chain
supported lower amount of CD25 on Treg cells, which usually
reached statistical significance, when compared to CD25
expression on control WT Treg cells (Figure 3C). Collectively,
these data indicated that mutations of all critical IL-2Rb tyrosine
residues resulted in sufficient IL-2R signal transduction to readily
support Treg cell development and peripheral homeostasis,
although they do not fully support upregulation of CD25.
IL-2 in concert with TGF-b is required for production of CD4+
Foxp3+ iTreg cells and leads to the induction of Foxp3 by
CD8+ T cells (Ahmadzadeh et al., 2007; Davidson et al., 2007;
Zheng et al., 2007). Therefore, the capacity of mutant IL-2R b-
chains to support development of iTreg cells was tested after
the culture of spleen cells with anti-CD3 in the presence of exog-
enous IL-2 and TGF-b (Figure 3D). When these activated T cells
were examined 48 hr later for Foxp3 expression, 30%–50% of
control WT CD4+ and CD8+ T cells expressed Foxp3. In marked
contrast, at least 80% fewer Foxp3+ cells were found in cultures
from T cells expressing mutant IL-2R b-chains. The higher
percentage of CD4+ Foxp3+ T cells with mutant IL-2Rb may in
part reflect survival of natural Treg cells within the spleen in
that there was essentially no induction of Foxp3 for CD8+
T cells bearing mutant IL-2R b-chains. Overall, these data
indicate that mutations of key tyrosine residues for IL-2R
signaling readily support development, maintenance, and
homeostasis of natural Treg cells but poorly supported produc-
tion of iTreg cells.
IL-2R Signaling by Treg Cells Bearing Mutant IL-2Rb
STAT5 activation is critical for Treg cell production (Burchill et al.,
2003; Burchill et al., 2007; Snow et al., 2003). We initially
confirmed that IL-2 readily induced sustained STAT5 phosphor-
ylation in thymic and peripheral Treg cells in control WTmice and
minimally induced pS6, a downstream target of the PI-3-kinase-
Akt pathway (Figure 4A). This latter result was expected because
of PTEN activity in Treg cells (Walsh et al., 2006). Quantitative
analysis of pSTAT5 revealed that thymic Treg cells activated
nearly 2-fold more pSTAT5 than peripheral Treg cells, indicating
that these Treg cells are more responsive to IL-2 (Figure 4B).
With respect to pSTAT5 activation by Treg cells expressing
mutant IL-2Rb chains, 15 min after IL-2 treatment, thymic and
peripheral Treg cells expressing 2RbY341 induced near normal
amounts of pSTAT5, whereas it was readily measurable but
significantly reduced in Treg cells expressing the other mutantIL-2Rb chains (Figures 4C and 4D). When Treg cells were acti-
vated with IL-2 for 60 min, pSTAT5 was further reduced in
comparison to control littermate Treg cells, especially for
2RbY395,498, 2RbY341,395,498, and 2RbDH. 2RbWT/Thymus mice
represent our previously well-characterized model in which the
proximal Lck promoter was used to drive transgenic WT IL-
2Rb preferentially to the thymus, thereby efficiently preventing
autoimmunity when expressed in IL-2Rb-deficient mice (Malek
et al., 2000; Malek et al., 2002). Treg cells from the thymus and
spleen of 2RbWT/Thymus mice also exhibited weak transient
STAT5 activation (Figure 4D). Collectively, these findings indi-
cate that weak transient STAT5 activation supported by mutant
IL-2Rb chains is sufficient to develop and maintain a population
of Treg cells that show considerable efficacy to suppress auto-
immune disease and suggest that these tyrosine residues may
normally function to sustain activation of STAT5 in Treg cells.
Functional Activity of Mutant IL-2Rb Chains on Effector
T Cells
The ability of themutant IL-2Rb chains to support Treg cell devel-
opment and function raised the question concerning their activity
on effector T cells. Therefore, we cultured spleen cells with anti-
CD3 and washed and recultured the resulting T cell blasts with
IL-2 to test their proliferative capacity to IL-2 (Figure 5A). T cell
blasts bearing mutant IL-2Rb showed marked impairment in
IL-2-dependent proliferation, with greater impairment with
increasing the number of Y/F mutations. This result is consis-
tent with a number of studies that have explored the role of
IL-2Rb signal transduction leading to T cell growth in IL-2-
dependent cell lines (Gaffen, 2001). These anti-CD3-activated
T cells were also directly examined for expression of two other
IL-2-dependent activities, i.e., upregulation of CD25 (Figure 5B)
and expression of granzyme B (Figure 5C). In each case, the
anti-CD3-activated T cells bearing mutant IL-2Rb chains ex-
pressed lower amounts of these molecules, reflecting impaired
IL-2R signaling in response to endogenous IL-2. The lowest
expression was always associated with the 2Rb341,395,498 muta-
tion. As a control, induction of CD69 was similar for all anti-CD3-
activated T cells bearing mutant IL-2Rb (Figure 5D). Collectively,
these findings confirm the importance of these tyrosine residues
and the H region in IL-2R signaling by conventional effector T
lymphocytes.
IL-2R Signaling by Effector T Cells Bearing
Mutant IL-2Rb
Immunoblot analysis was also performed for a number of defined
signaling intermediates in the IL-2 signal transduction pathway.
For these experiments, anti-CD3 T cell blasts were cultured
overnight in IL-4 and rested for 4 hr before restimulation with
IL-2 because this aided detection of downstream targets of the
adaptor Shc, i.e., phosphorylated (p)-MAPK, pAKT, p70S6
kinase, pS6, which are also induced by TCR signaling. IL-2-
dependent signaling by T cell blasts from C57BL/6 and
2RbY341,395,498 mice was initially compared. With respect to acti-
vation of STAT5, strong sustained activation of pSTAT5 was
noted for the C57BL/6 T cell blasts, whereas the activation of
pSTAT5 by 2Rb341,395,498 T cell blasts was initially strong, but
not sustained as evident 60 min after stimulation by IL-2
(Figure 6A, left). In contrast, IL-2-dependent activation of pShc,Immunity 30, 204–217, February 20, 2009 ª2009 Elsevier Inc. 209
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IL-2R Signaling and T Regulatory CellsFigure 4. Signaling by CD4+Foxp3+ T Cells Bearing Mutant IL-2Rb
Thymocytes and spleen cells from the indicated mice were cultured in medium for 30 min and then stimulated with an excess of IL-2 (10 ng/ml) for the indicated
time.
(A) Representative pSTAT5 and pS6 after gating on normal B6 CD4+Foxp3+ T cells.
(B) Summary of all experiments (n = 3) for pSTAT5 activation byWT Treg cells in which theMFI of pSTAT5 staining at 15min by thymic Treg cells was normalized to
a value of 1 and used to compare all samples.
(C) Representative comparison of IL-2-dependent pSTAT5 after gating on CD4+Foxp+ Treg cells from B6 and mutant IL-2Rb transgenic mice.
(D) Summary of all comparisons in which theMFI of pSTAT5 staining at 15min by control Il2rb+/+ or +/was normalize to a value of 1 and used to compare staining
by Treg cells bearing mutant IL-2Rb. Data are the mean ± SEM of two to five mice/group <16 weeks of age derived from at least two independent experiments.pATK, pP70S6 kinase, pS6, or pMAPKwas strong and sustained
only for the C57BL/6 control T cell blasts. A slightly different
pattern of results was noted for T cell blasts from 2Rb341 and
2Rb395,498 mice. Again, pSTAT5 was readily detected 15 min
after IL-2 stimulation for both mutant IL-2Rb chains (Figure 6A,
right). With respect to the 2RbY341, pSTAT5 was somewhat
more sustained than seen for IL-2Rb395,498, but there was no
obvious activation of any other phosphoproteins in the IL-2
pathway. In contrast, 2RbY395,498 mutation supported some acti-
vation of pShc, that was most obvious in founder #5 with higher210 Immunity 30, 204–217, February 20, 2009 ª2009 Elsevier Inc.expression of the 2RbY395,498 transgene, and 2RbY395,498 also
supported detectable, but weak, activation of signaling mole-
cules ascribed to the adaptor Shc, i.e., pMAPK, and pS6. As
a control, IL-2-driven signaling by 2RbWT T cell blasts was essen-
tially comparable to that seen for C57BL/6 T cell blasts.
We used mAbs specific for pSTAT5 and pS6 to examine IL-2R
signaling by CD4+ and CD8+ T cells. With respect to pSTAT5,
these data closely approximated the findings from the immuno-
blots and confirmed the transient nature of STAT5 phosphoryla-
tion by each of the mutant IL-2Rb chains (Figure 6B). Thus, weak
Immunity
IL-2R Signaling and T Regulatory CellsFigure 5. Proliferative and Functional Responses by T Cell Blasts Bearing Mutant IL-2Rb
Spleen cells from the indicated mice were culture with anti-CD3 for 48 hr. In (A), the activated T cells were washed and recultured in the indicated level of IL-2 for
24 hr. 3H-thymidine was added during the last 4 hr of culture. Each data point represents the mean from three independent experiments, in which the highest
response was normalized to 100%.The activated CD4+ and CD8+ spleen cells were stained for (B) CD25, (C) granzyme B (Gzmb), or (D) CD69. TheMFI of staining
by control ll2rb+/+ or +/ was normalized to a value of 1 and used to compare staining by T cells bearing mutant IL-2Rb. Data in (B)–(D) are from at least three
separate experiments.transient tyrosine-independent STAT5 activation is not a prop-
erty unique to Treg cells. Furthermore, the quantitative pattern
of pSTAT5 was comparable for both activated CD4+ and CD8+
T cells (Figure 6C). In contrast, pS6 was more strikingly upregu-
lated in CD8+ T cells, and this was partially maintained in CD8+
T cells bearing IL-2RbDH, but not bearing any of the tyrosine
mutations, implicating a role for the H region in negative regula-
tion of IL-2R signaling. The finding of greater IL-2-dependent
activation of the PI-3-kinase-Akt pathway by the CD8+ T cells
provides a potential molecular explanation for our consistent
observation that CD8+ T cells rapidly outnumber CD4+ T cells
in anti-CD3-stimulated mixed cultures in vitro (not shown) and
that CD8+ T cells showed a greater dependence on IL-2 for
expansion after superantigen stimulation of T cells in vivo (Jin
et al., 2006). Collectively, these data indicate that initial STAT5
activation readily occurs without a strict requirement for any of
the three key functional tyrosine residues in the cytoplasmic
tail of IL-2Rb and suggest that these tyrosine residues may func-
tion to sustain activation of STAT5 and the MAPK and PI-3K-Akt
pathways in effector T cells.
Gene Expression Profiling of Treg and T Effector Cells
with Impaired IL-2R
To further evaluate the role of IL-2R signal in Treg cells, we ob-
tained Affymetrix gene expression profiles from CD4+CD25hiTreg cells directly isolated from the spleen of C57BL/6 WT or
2RbWT/Thymus mice by FACS sorting. These cells were always
>99% CD4+CD25hi and typically are at least 95% Foxp3+ cells.
To compare these findings to the gene expression profile for T
effector cells, we also activated the spleens with anti-CD3 for
48 hr and then isolated the activated CD4+CD25+ T cells to
>99% purity by FACS sorting. The 2RbWT/Thymus mice were
chosen for this analysis because their Treg cells showed tran-
sient STAT5 activation that was similar to 2Rb395,498 and
2Rb341,395,498 Treg cells (Figure 4D), and therefore permitted
comparsion of the Treg data to previous gene expression anal-
ysis of IL-2Rb-dependent genes based on 2RbWT/Thymus effector
cells (Gong and Malek, 2007). These analyses indicate that 353
(254 up and 99 down) and 553 (205 up and 348 down) Affymetrix
targets were IL-2 dependent byR2-fold (p < 0.05, t test), repre-
senting 285 and 421 distinct genes for Treg and T effector cells,
respectively (Figure 7A). These gene lists for Treg and T effector
cells are shown in Tables S1 and S2. Because 2RbWT/Thymus Treg
cell development and function is outwardly normal, we were
somewhat surprised by the substantial number of IL-2-
dependent genes in the peripheral Treg cells. This finding indi-
cates that there are many targets in 2RbWT/Thymus Treg cells
that are not properly expressed with minimal IL-2R signaling.
The Treg cell transcriptional signature was determined by
gene expression profiling of a variety of cells, behaving likeImmunity 30, 204–217, February 20, 2009 ª2009 Elsevier Inc. 211
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IL-2R Signaling and T Regulatory CellsFigure 6. IL-2-Dependent Signaling by T Cell Blasts Bearing Mutant IL-2Rb
(A) Spleen cells from the indicated mice were cultured with anti-CD3 for 48 hr. The T cells were isolated by magnetic bead sorting with anti-Thy-1.2, cultured in
IL-4 for 24 hr, and washed and ‘‘rested’’ in medium for 4 hr. These T cells were cultured with IL-2 for the indicated time and cytoplasmic extracts were prepared.212 Immunity 30, 204–217, February 20, 2009 ª2009 Elsevier Inc.
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IL-2R Signaling and T Regulatory CellsTreg cells, obtained directly ex vivo or after activation in vitro (Hill
et al., 2007) and showed that the Treg cell signature contained
only a subset of genes that correlated with Foxp3 expression.
Part of the Treg cell signature was shown to be distinctively influ-
enced by IL-2, TGF-b, and T cell activation in general. Compar-
ison of our gene lists with this recently published Treg cell tran-
scriptional signature (Hill et al., 2007) revealed a striking overlap
in gene expression profiles (Figure 7A); 19.1% (92 of 482) and
14.3% (69 of 482) of the IL-2-dependent genes in Treg and T
effector cells, respectively, overlapped with the Treg transcrip-
tional signature. These two sets of IL-2-dependent targets, which
overlap with the Treg cell transcriptional signature, were
mostly distinct. Currently, 29,122 mouse genes have been
annotated on the basis of nucleotide sequence by Mouse
Genome Informatics (MGI). The 482 genes of the Treg cell
transcription signature represent 1.65% of the total number
of genes. Thus, the 19.1% and 14.3% overlap with Treg (p =
2.53 1053) and T cell effector (p = 6.13 1037) genes is highly
significant (Fisher’s exact test) and is consistent with IL-2 criti-
cally regulating important characteristics of Treg cells. Further-
more, 10.5% (44 of 421) of IL-2-dependent Treg genes overlap
with IL-2-dependent T cell effector genes and reciprocally
15.4% (44 of 285) of IL-2-dependent T cell effector genes over-
lap with Treg cells, and these percentages are slightly lower than
compared to their overlap with the Treg transcriptional signa-
ture. This degree of overlap was also highly significant (p at least
9.1 3 1022; Fisher’s exact test), in light of the fact that these
sets of genes represent 0.98% and 1.44% of all mouse genes.
This finding suggests a mechanism of important overlapping,
but mainly distinctive, processes that depend on IL-2R signaling
in Treg and T effector cells and these distinctive IL-2-dependent
processes are both reflected in the Treg cell transcriptional
signature.
We plotted the past data (Hill et al., 2007) of the Treg cell tran-
scriptional signature that represent 603 Affymetrix targets as
a function to their published correlation to Foxp3 expression
(Figure 7B, both graphs, lightly shaded curves). From 30–40
targets span nearly the entire range of high to low correlation
to Foxp3. We also then similarly plotted the IL-2-dependent
targets from Treg (Figure 7B, upper graph, dark curve) and T
effector cells (Figure 7B, lower graph, dark curve) that overlap-
pedwith the Treg cell transcriptional signature. A greater propor-
tion of the IL-2-dependent Affymetrix targets in Treg cells
(56.3%) more closely correlated (R0.4) with Foxp3 expression
of the Treg cell transcriptional signature than for IL-2-dependent
genes associated with T effector cells (42.8%), with the latter
showing a uniform distribution of IL-2-dependent targets in rela-
tionship to their correlation to Foxp3. This result is also consis-
tent with unique aspects the of IL-2-dependent Treg and T cell
effector gene programs intersecting with the Treg cell transcrip-
tional signature.
With respect to Gene Ontology classification, IL-2-dependent
targets of Treg and T effector cells were overrepresented bygenes with known function in the immune system (Z scores:
3.58, Treg cells upregulated targets; 6.91 and 4.17, T effector
cells up and downregulated targets, respectively) (Figure 7C).
Those targets that were shared between Treg and T effector cells
are indicated by shading, whereas those targets that overlapped
with the Treg cell transcriptional signature are underlined
(Figure 7C). Unique to T effectors cells was the overexpression
of IL-2-dependent upregulated targets in amine metabolism
(Z score: 3.88) and cell differentiation (Z score: 4.06). Treg cells
showed unique overrepresentation of IL-2-dependent upregu-
lated targets involved in cytoskeleton (Z score: 3.86) and cell
cycle (Z score: 5.29) and downregulated targets for cell death
(Z score: 3.16). The latter two groups are consistent with
a possible direct role of IL-2 in contributing to homeostatic prolif-
eration by peripheral Treg cells. Several well-characterized Treg
related targets such as Foxp3, Tgfb1, CD25, Tnfrsf18 (GITR),
Socs2, and Fgl2 were expressed at near normal amounts in
2RbWT/Thymus. This finding probably explains the generally effec-
tive development and function of these Treg cells. Because we
showed that both Foxp3 and CD25 are dependent upon IL-2
signaling (Figure 3), it is likely that these and perhaps other
Treg cell-related targets, e.g., Socs2, are effectively regulated
by lower IL-2R signaling associated with 2RbWT/Thymus and the
other mutant IL-2Rb chains. Collectively, these data indicate
that a substantial portion of the gene program associated with
Treg cells depends on IL-2, but this list does not include several
important IL-2-dependent targets that are readily responsive to
low IL-2R signaling.
DISCUSSION
Here, we demonstrate that both thymic Treg cell development
and their peripheral homeostasis effectively occur by IL-2Rs
that harbor mutations of key tyrosine residues in the cytoplasmic
tail of IL-2Rb that are required for optimal signal transduction.
Mutation of all three of these tyrosine residues still led to weak
transient STAT5 activation, indicating that IL-2R signaling was
not completely abrogated. Thus, these data demonstrate that
key IL-2-dependent targets in Treg cells are indexed to a low
IL-2R signaling threshold. One of these targets is probably
Foxp3 because Foxp3 expression depends in part on STAT5
activation (Burchill et al., 2007; Yao et al., 2007; Zorn et al.,
2006), andwe show that Foxp3 was upregulated to normal levels
in thymic and peripheral Treg cells bearingmutant IL-2Rb chains.
The indexing of Treg cells to a low IL-2R signaling threshold
provides an explanation concerning how Treg cells effectively
utilize an essential cytokine that is transiently and perhaps mini-
mally expressed. For example, there are very few IL-2 producing
cells in the thymus, and such cells are not abundant in peripheral
immune tissues (D’Souza and Lefrancois, 2004; Sojka et al.,
2004; Yang-Snyder and Rothenberg, 1998). More specifically
to Treg cells, one of their suppressive mechanisms is to inhibit
IL-2 production by autoreactive or effector T cells (ThorntonImmunoblots were probedwithmAbs to the indicated phosphotyrosine proteins. AmAb to unmodified STAT5 served as a loading control. Data are representative
of two experiments.
(B) The indicated anti-CD3-activated spleen cells were cultured in medium for 4 hr, stimulated with IL-2 for the indicated time, and stained for pSTAT5 and pS6.
(C) Summary of all experiments in which theMFI of pSTAT5 staining at 15min by control Il2rb+/+ or +/was normalized to a value of 1 and used to compare staining
by T cells bearing mutant IL-2Rb. Data are the mean ± SEM ofR3 mice/group <16 weeks of age derived from at least three separate experiments.Immunity 30, 204–217, February 20, 2009 ª2009 Elsevier Inc. 213
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IL-2R Signaling and T Regulatory CellsFigure 7. IL-2-Dependent mRNA in Treg and T Effector Cells
(A) IL-2-dependent genes (>2-fold) from Treg and CD4+ T effector cells that overlap with each other and the Treg cell gene signature.
(B) IL-2 dependent targets (dark curves) that overlap with the Treg cell transcriptional signature (lightly shaded curves). The overlapping Treg (upper graph) and T
effector (lower graph) cell targets versus all targets of the Treg cell transcriptional signature plotted as a function of their correlation to Foxp3 expression as
reported by Hill et al., 2007 are shown.
(C) Functional groups of IL-2-dependent (>2-fold) differentially expressed genes by Treg andCD4+ T effector cells. Shaded genes represent those transcripts that
overlap between IL-2-dependent Treg and T effector cells. Underlined genes were identified in the Treg cell transcriptional signature. Data represent three inde-
pendent biological replicates/group.and Shevach, 2000). Thus, Treg cells probably exist in an IL-2-
poor environment, yet IL-2 is essential for thymic maturation
and subsequent homeostasis in the periphery. Treg cells, there-
fore, appear to adapt to low IL-2 through fully inducing andmain-
taining Foxp3 by a minimal requirement for IL-2-dependent
pSTAT5 activation. As such, this mechanism links Foxp3, which
enforces and maintains the Treg cell-suppressive program214 Immunity 30, 204–217, February 20, 2009 ª2009 Elsevier Inc.(Gavin et al., 2007; Lin et al., 2007), to a low threshold for IL-2R
signal transduction.
The effectiveness of a low IL-2R signaling threshold for Treg
cells has important implications in immunotherapy that targets
the IL-2 or the IL-2R. First, immunotherapy based on anti-IL-
2R blockade is unlikely to fully inhibit IL-2 binding to the IL-2R
or even approach the degree of IL-2R signaling inhibition
Immunity
IL-2R Signaling and T Regulatory Cellsassociated with our IL-2Rb mutants that readily support and
maintain Treg cells in vivo. Thus, Treg cells are likely to be
substantially resistant to approaches that aim to inhibit T cell
immunity by directly blocking the IL-2R. Indeed, many clinical
protocols have utilized humanized mAb to IL-2Ra (Waldmann,
2007) without noting side effects consistent with impaired Treg
cells, e.g., T cell activation or autoimmunity. Second, Treg cells
are predicted to be relatively responsive to IL-2-based therapy
and administering low-dose IL-2 might represent a means to
enhance Treg cell function in vivo. In this regard, treatment of
NOD mice with a low concentration of an agonist complex of
IL-2 and anti-IL-2 prevented autoimmune diabetes by enhancing
Treg cell survival and function (Tang et al., 2008).
Our study shows that chronic low IL-2R signaling is remark-
ably effective in producing an effective population of Treg cells.
Nevertheless, there are important biological consequences of
such impaired IL-2R function. Notably, we consistently observed
an increase in an activated T cell phenotype and inflammatory
infiltrates, most often in the lung and salivary gland, in progeny
of older mice that expressedmutant IL-2R b-chains. These types
of abnormalities were also reported for Il2/ and Il2ra/ mice
(Sharma et al., 2006) and were also seen in several younger
Il2rb/ mice, as an apparent early consequence of their
systemic autoimmunity. Thus, impaired chronic IL-2R signaling
over a long time frame leads to symptoms consistent with
organ-specific autoimmunity, which in our model appears to
be analogous to Sjo¨gren’s syndrome. In a related manner,
decreased IL-2 production has been associated with the Idd3
locus of NODmice that impairs Treg cell function and contributes
to autoimmune diabetes (Yamanouchi et al., 2007). These find-
ings also raise the possibility that the recent association of
polymorphisms in human CD25 with susceptibility to several
autoimmune diseases might ultimately be reflected by chronic
lower IL-2R signaling.
Past work is consistent with a model in which Treg cells
depend primarily on IL-2-dependent activation of STAT5, and
our study is consistent with that view. However, the basis by
which IL-2R-dependent STAT5 activation successfully supports
Treg cell production remains poorly understood. Another impor-
tant aspect of this study is that we show that Treg cells utilize
a unique mechanism to activate STAT5 for their development
and homeostasis, but this signaling is insufficient to support IL-
2-dependent T cell growth by conventional T cells or develop-
ment of iTreg cells in vitro. Weak transient STAT5 activation
occurred after mutations of three critical tyrosine residues in
the cytoplasmic tail of IL-2Rb, and this IL-2R readily supported
Treg cell production in vivo. Deletion of the distal 123 amino
acids of the cytoplasmic tail of IL-2Rb, i.e., the H region,
including the two dominant tyrosine residues for STAT5 docking,
also supported transient STAT5 activation and Treg cell produc-
tion. These results demonstrates that initial STAT5 activation
does not depend upon some other undefined interaction within
the H region of IL-2Rb and provides a mechanistic explanation
for past work that showed that domain deletions of the A or H
regions of the IL-2Rb cytoplasmic tail also prevented autoim-
mune symptoms after expression in Il2rb/ mice (Fujii et al.,
1998). Overall these findings are consistent with amodel in which
the initial IL-2R-dependent activation of STAT5 is independent of
docking with these three tyrosine resides and may be indepen-dent of dockingwith the cytoplasmic tail of IL-2Rb. Nevertheless,
phosphorylation of these tyrosine residues ultimately promotes
docking of STAT5 and other signaling molecules, such as the
adaptor Shc, to assemble a complex for sustained IL-2R signal
transduction. The basis for IL-2Rb tyrosine-independent activa-
tion of STAT5 remains to be determined. One possibility is a tyro-
sine-independent H region-independent association of STAT5
with IL-2Rb. Alternatively, past studies examining gp160 in cell
lines that overexpressed receptor-related components provided
evidence for direct Jak-1 activation of STAT5 (Fujitani et al.,
1997), and perhaps this is also operative for the IL-2R.
Gene expression profiling of WT versus 2RbWT/Thymus periph-
eral Treg cells demonstrated that a substantial number of targets
remain IL-2 dependent. Thus, the capacity of weak transient
STAT5 activation to readily support predominantly normal Treg
cell development and homeostasis is probably due to the sensi-
tivity of a few key targets, e.g., Foxp3 as discussed above, to this
low IL-2R signal transduction rather than a global control of the
IL-2 program in Treg cells by low threshold IL-2R signaling.
The types of genes dependent upon IL-2 included those related
to the immune system and cell cycle. This latter finding corre-
sponds to past work in which we showed that WT peripheral
Treg cells exhibited substantially greater BrdU incorporation
and proliferation than 2RbWT/Thymus Treg cells (Bayer et al.,
2007) and is consistent with the view that IL-2 is normally an
important mediator of Treg cell homeostasis. Past gene profiling
of IL-2-dependent genes in Treg cells also reached a similar
conclusion related to Treg cell growth and the cell cycle (Fonte-
not et al., 2005). However, many of the key IL-2-dependent
targets identified previously were not found as differentially ex-
pressed in our gene-array analysis. We believe that this is ac-
counted for in the distinct protocols utilized. We examined
Treg cells from autoimmune-free mice with chronic long-term-
impaired IL-2R signaling. Past work evaluated IL-2 dependent
targets after autoimmune IL-2-deficient mice received a brief
acute exposure to IL-2 (Fontenot et al., 2005).
Direct assessment of IL-2R signal transduction in CD4+ Treg
and T effector cells closely approximate each other. However,
the IL-2-dependent targets in these cell populations were largely
distinctive, but with a high overlap (10%–15%). This latter finding
is consistent with IL-2 controlling several common processes in
these two cell types. Evenmore striking was the overlap (20%) of
IL-2-dependent transcripts in Treg cells with the recently pub-
lished Treg cell transcriptional signature (Hill et al., 2007). Thus,
our study places on firm ground the importance of IL-2 in regu-
lating a substantial portion of the Treg cell gene program.
EXPERIMENTAL PROCEDURES
Mice
C57BL/6 mice were obtained from the Jackson Laboratories. C57BL/6 IL-
2Rb-deficient mice were previously described (Suzuki et al., 1995) and main-
tained in our laboratory as autoimmune-free breeding stock by adoptive
transfer of CD4+CD25+ Treg or CD4+ T cells at birth (Malek et al., 2002).
2RbWT/Thymus mice represent Il2rb/ mice that express thymus-targeted
transgenic WT IL-2Rb and have been previously described (Malek et al.,
2000; Malek et al., 2002). To produce other transgenic mice, we subcloned
full-length mouse IL-2Rb cDNA into pENTR (Invitrogen). As required, this
cDNA was subjected to site directed mutagenesis with the QuikChange site-
directed mutagenesis kit (Stratagene) to change the indicated tyrosine codonsImmunity 30, 204–217, February 20, 2009 ª2009 Elsevier Inc. 215
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tion (Figure 1A), where position 1 represents the first amino acid after removal
of the 24 amino acid signal peptide. All mutations were verified by DNA
sequencing. The CD2 minigene cassette vector p29D2(Sal), kindly provided
by P. Love and A. Singer, wasmodified to replace the EcoRI/SalI fragment with
the Gateway Cassette (Invitrogen) to permit directional recombination-based
subcloning of each cDNA within pENTR. The purified transgenic expression
cassette was microinjected into (B6 3 SJL)F2 oocytes. Transgenic founders
were identified by PCR and backcrossed three to five generations to C57BL/
6 Il2rb/ mice. Animal studies were approved by the Institutional Animal
Care and Use Committee at the University of Miami.
Cell Purification, Cell Culture, and Functional Assays
CD4+ CD25+ Treg cells were purified (typicallyR90%) by depletion of B cells
and CD8+ T cells followed by magnetic-bead-based positive selection of
CD25+ T cells (Malek et al., 2002). For the microarray analysis, these cells
were subjected to further purification by FACS sorting for CD4+ CD25high
T cells. To prepare activated T cells, we cultured spleen cells (2 3 106 cells/
well) with anti-CD3 in 24-well culture plates for 48 hr (Malek et al., 2001). To
measure intracellular granzyme B, prior to staining we recultured these acti-
vated T cells at 1 3 106 cells/well in 24 well plates for 4 hr with PMA (50 ng/
ml) and ionomycin (1 mM) in the presence of brefeldin A (GolgiPLug, BD-
Biosciences). To assess IL-2-dependent proliferation, we washed the anti-
CD3-activated spleen cells three times and recultured them (2 3 104 cell/
well) for 24 hr with the indicated concentration of IL-2 (Peprotech) in 96-well
plates for 24 hr, during which 3H-thymidine was added for the final 4 hr of
culture (Malek et al., 2001). For immunoblotting, T cells from the anti-CD3-acti-
vated spleen cells were purified by positive selection with anti-Thy-1.2
magnetic beads (Miltenyi Biotec). These purified T cells were cultured over-
night at 13 106 cells/ml in T25 flasks in 5–10 ml of medium containing mouse
IL-4 (10 ng/ml). For iTreg cells, spleen cells were cultured with anti-CD3, TGF-b
(5 ng/ml; Peprotech), and IL-2 (10 ng/ml) for 48 hr.
FACS Analysis
Staining for cell-surface markers with mAbs from BD PharMingen or eBio-
sciences, intracellular granzyme B (Invitrogen), or for pSTAT5 (pY694, BD
PharMingen) or pS6 kinase (Cell Signaling) were performed as previously
described (Bayer et al., 2007; Gong and Malek, 2007). Intracellular staining
for Foxp3 (eBiosciences) was performed according to the manufacturer’s
instructions. Cells were analyzed with a Becton Dickinson LSR1 or LSR2
and CellQuest or Diva software. Typically, at least 50,000–100,000 events
were collected per sample.
Immunoblots
Cell extracts (1003 106 cells/ml) were prepared with M-PERB protein extraction
reagent with Halt protease and a phosphatase inhibitor cocktail (Pierce).
Immunoblotting was performed on reducing 10% SDS-PAGE gels after 2 3
106 cell equivalents were loaded per lane as previously described (Yu and
Malek, 2001). The blots were blocked and then incubated with the indicated
primary mAb (all from Cell Signaling). After washing, the blots were then incu-
bated with goat anti-rabbit HRP (Cell Signaling). Bands were developed by
incubation of the blots with ECL chemiluminescence reagent (GE-Healthcare
Bio-Sciences Corp.) according to the manufacturer’s instructions.
DNA Microarray Analysis
Total mRNA was isolated by TRIzol reagent and further purified with RNAeasy
Minikit (QIAGEN). RNA quality and quantity were assessed by analysis with an
Agilent 2100 BioAnalyzer. A single round of linear probe amplification with
1–2 mg of total RNA (Affymetrix) was used for each RNA sample. Probe prep-
aration and microarray analysis were performed at Expression Analysis with
the 430 2.0 Affymetrix chip. We detected fluorescent images in a GeneChip
Scanner 3000 using GCOS 1.3 software (Affymetrix) to extract the expression
data. An estimate of signal for each transcript was calculated and then normal-
ized with the GCRMA method of the Bioconductor R package. Two group
comparisons of the transformed data were performed for three biological repli-
cate samples by paired t tests. Genes expressed >2.0-fold up or down (p <
0.05) between the C57BL/6 WT and 2RbWT/Thymus were considered differen-
tially expressed genes.216 Immunity 30, 204–217, February 20, 2009 ª2009 Elsevier Inc.Statistical Analysis
Unless otherwise noted, all statistical analysis of the data in Figures 1–6 were
performed by a one-way ANOVA with Tukey’s multiple comparison test.
Statistically significant differences (p < 0.05) for comparison to IL-2Rb+/+ or +/
littermate controls are designated by an asterisk in the graphs.
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Microarray data are available from the NCBI/GEO data base (accession
number GSE14350).
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